AGN.AS (Aegon Ltd.) — Investment Thesis

Scored 2026-02-24 | Entry price: EUR 6.39 | Composite: 4.0/5 (20/25)

Hypothesis

Aegon is a post-transformation European insurer trading at crisis-level multiples (forward P/E 6x) despite having successfully restructured. The market prices in negative growth (-0.2% implied) for a company that is actively shrinking its share count by ~7%/year and just reported results that "surpassed targets." The thesis is that the market hasn't caught up to the new, simpler Aegon — and the aggressive capital return program (buybacks + dividends) will force a re-rating over 2-3 years.

Why This Is Good

The setup

• 6/7 Graham defensive filters passed — the strongest quantitative score in the STOXX 600 quick screen
• Forward P/E of 6.19x — the market is pricing in a deteriorating future that contradicts the actual earnings trajectory
• Margin of safety: 82.7% — price is deeply below Graham intrinsic value
• P/E × P/B = 8.9 — well under Graham's 22.5 blended ceiling

The catalyst

• 25% share count reduction since 2021 — 2.01B shares → 1.51B shares through aggressive buybacks funded by US business disposal proceeds
• UK business sale (~GBP 2.7B) in progress with multiple bidders — proceeds will fund further buybacks or a special dividend
• EUR 227M expanded buyback announced January 2026
• FY2025 results beat — reported Feb 19, 2026 as "surpassing targets with strong growth"

The income

• 6.6% dividend yield at a 45% payout ratio — well covered, with room to grow
• Total capital return yield ~15% — EUR 925M buybacks + EUR 521M dividends returned in 2024 alone vs EUR 9.66B market cap
• Dividend has been growing ~20%/year since 2021 restart (EUR 0.20 → EUR 0.42)

Why Graham Thinks It's Good

1. Adequate size — EUR 9.7B market cap, EUR 13B+ revenue
2. Strong financial condition — net financial debt only EUR 1.3B against EUR 9.2B equity (0.14x leverage on actual debt, not policyholder liabilities)
3. Dividend record — 24 years of payments (interrupted by GFC bailout 2009-2011 and COVID regulatory cut 2020)
4. Earnings growth — 188% 10-year cumulative growth
5. Moderate P/E — 8.2x trailing, 6.2x forward (well under 15x)
6. Moderate P/B — 1.09x (under 1.5x)
7. Margin of safety — earnings yield (~16%) massively exceeds bond yields (~3-4%), giving a 12%+ spread

The only filter it fails is earnings stability — FY2022 and FY2023 had GAAP losses, but these were driven by the IFRS 17 accounting transition and US business disposal write-offs, not operating deterioration. Continuing operations were profitable throughout.

Graham's implied growth formula: (P/E - 8.5) / 2 = (8.2 - 8.5) / 2 = -0.2%. The market prices in a shrinking business. If Aegon merely stays flat, it's undervalued. If buyback-driven EPS growth continues at 5-7%/year, it's severely undervalued.

Why Paleologo Thinks It's Good

1. Kelly criterion shows strong positive edge — full Kelly 33.9%, half Kelly 17.0%. Edge per EUR risked: +0.383. This is a high-conviction bet by the math.
2. Low correlation to tech/growth — beta 0.62, European insurer. Adds genuine diversification to a portfolio, improving the Information Ratio through breadth.
3. Low volatility — the half-Kelly allocation is large because the risk/reward is favorable relative to the variance. Paleologo's framework rewards high expected return per unit of risk.
4. Fundamental Law of Active Management — adding a low-correlation, positive-alpha position to the portfolio increases IR = IC × sqrt(n × T). Each independent bet with positive edge improves the portfolio.

Entry Plan

Pre-buy checklist (re-check on purchase day):

• [ ] Price still below EUR 7.50 (if above, re-run Kelly with updated inputs)
• [ ] No dividend cut announcement since analysis date
• [ ] Buyback program still active
• [ ] UK sale process still on track
• [ ] No solvency ratio concerns in latest reporting

Exit Targets

Profit targets (sell in thirds)

Time-based exit

• Re-score at every semi-annual earnings report
• Exit if no progress by September 2027 (18 months) — the catalyst thesis (UK sale, buyback re-rating) should have played out by then

Red Flags to Exit

EXIT immediately

• Dividend cut or suspension — the capital return thesis is the core of this investment. If management cuts the dividend, the thesis is broken.
• Buyback program cancelled — the 25% share reduction is the primary driver of per-share value creation. If this stops, the re-rating catalyst disappears.
• Solvency ratio breach — if Aegon's Solvency II ratio drops below regulatory minimums, the company enters a crisis that overrides all other considerations.

RE-SCORE (may lead to exit)

• UK business sale falls through — near-term catalyst weakened, but the core thesis (cheap + buybacks) still holds. Re-score and reassess.
• Two consecutive earnings misses — signals the "surpassing targets" narrative was a one-off. Re-score all 5 qualitative factors.
• Interest rates drop sharply (>200bps) — Aegon's EUR 5.8B investment income is rate-sensitive. A sharp rate cut environment compresses this structural tailwind.

TRIM to quarter-Kelly

• Any qualitative factor drops below 3/5 on re-scoring — the margin of safety in the score has eroded.
• P/E expands above 12x with no earnings growth — multiple expansion without fundamental improvement means you're relying on sentiment, not value.

NOT a reason to exit

• Price drops 20-30% with unchanged fundamentals — this INCREASES your margin of safety. Graham says buy more, not sell. The phased entry plan naturally buys dips.